However, choosing a suitable neoantigen in CMMRD patients is particularly difficult because, in contrast to LS patients in whom only (pre)malignant cells are completely MMR-deficient, in CMMRD patients MMR deficiency is present in all cells and therefore the neoantigens could be expressed in healthy cells of the patient as well. This evidence concerns the gene MRC1 and Leigh syndrome.